<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical trials on FinanClub</title>
    <link>https://finan.club/tags/clinical-trials/</link>
    <description>Recent content in Clinical trials on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 23 Mar 2024 09:04:57 +0000</lastBuildDate><atom:link href="https://finan.club/tags/clinical-trials/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Sat, 23 Mar 2024 09:04:57 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:437
Chances: Recent publication of preclinical data in Science indicates potential for combination therapy to manage HIV without antiretroviral treatment. Phase 1 pilot study showed potential of N-803 combined with natural killer cells to reduce viral load in people living with HIV. Enrollment and initial follow-up completed for safety portions of a clinical trial studying ImmunityBio’s investigational cancer vaccine and IL-15 superagonist for participants with Lynch syndrome.</description>
    </item>
    
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Mon, 11 Mar 2024 09:03:54 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:113
Chances: TG Therapeutics, Inc. has announced the presentation of data from the ULTIMATE I &amp;amp; II Phase 3 trials evaluating BRIUMVI® in patients with relapsing forms of multiple sclerosis, indicating potential positive outcomes from the trials. The company has reported strong financial results, with BRIUMVI U.</description>
    </item>
    
    <item>
      <title>SANA</title>
      <link>https://finan.club/us/sana/</link>
      <pubDate>Sat, 02 Mar 2024 09:02:41 +0000</pubDate>
      
      <guid>https://finan.club/us/sana/</guid>
      <description>score:46
Chances: Sana Biotechnology has successfully cleared IND for B-cell mediated autoimmune diseases with initial clinical data expected in 2024 Early data from ongoing ARDENT trial suggests the ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy Risks: Markets are awaiting the latest inflation numbers and the debate regarding soft vs hard landing is expected to persist on Wall Street High institutional ownership implies Sana Biotechnology&amp;rsquo;s stock price is sensitive to their decisions Score:46 chances characters count - risks characters count = 46</description>
    </item>
    
    <item>
      <title>ARWR</title>
      <link>https://finan.club/us/arwr/</link>
      <pubDate>Thu, 04 Jan 2024 09:10:03 +0000</pubDate>
      
      <guid>https://finan.club/us/arwr/</guid>
      <description>score:114
Chances: The company has successfully priced an underwritten registered offering, indicating strong investor interest and potential for significant capital influx. The filing of an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB demonstrates progress in the company’s pipeline development.</description>
    </item>
    
  </channel>
</rss>
